Targeting the IL-6/STAT3 pathway is a potential therapeutic strategy for HCC, involving interventions like IL-6 inhibitors (cetuximab, ADL518), IL-6R inhibitor (tocilizumab), JAK inhibitors (ruxolitinib), and direct STAT3 inhibitors (LLL12, C188-9) (140). This evidence concerns the gene IL6 and hepatocellular carcinoma.